TOURMALINE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.68 USD | -2.00% |
|
+1.49% | -40.11% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 532.4 | 402.1 | - | - |
| Enterprise Value (EV) 1 | 532.4 | 86.44 | -34.66 | 74.44 |
| P/E ratio | -2.95 x | -5.32 x | -5.12 x | -4.5 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 40.2 x | 40.2 x |
| EV / Revenue | - | - | -3.47 x | 7.44 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -1.3 x | 0.51 x | -1.07 x |
| FCF Yield | - | -77.1% | 196% | -93.1% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 20,337 | 25,647 | - | - |
| Reference price 2 | 26.18 | 15.68 | 15.68 | 15.68 |
| Announcement Date | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 10 | 10 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -45.41 | -70.65 | -80.45 | -92.98 |
| Operating Margin | - | - | - | -804.54% | -929.78% |
| Earnings before Tax (EBT) 1 | - | -42.12 | -71.81 | -99.97 | -107.5 |
| Net income 1 | -19.7 | -42.12 | -66.27 | -81.34 | -97.74 |
| Net margin | - | - | - | -813.43% | -977.43% |
| EPS 2 | -1.790 | -8.870 | -2.948 | -3.062 | -3.488 |
| Free Cash Flow 1 | - | - | -66.67 | -68 | -69.33 |
| FCF margin | - | - | - | -680% | -693.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 7/20/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -8.932 | -14.89 | -15.79 | -17.03 | -18.16 | -19.68 | -14.14 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.015 | -12.9 | -15.68 | -17.02 | -18.49 | -20.63 | -14.14 |
| Net income 1 | -7.015 | -12.9 | -15.03 | -15.79 | -16.96 | -18.5 | -14.14 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -1.640 | -0.8100 | -0.6680 | -0.6900 | -0.7320 | -0.7860 | -0.8600 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/14/23 | 3/19/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 316 | 437 | 328 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -66.7 | -68 | -69.3 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share 2 | - | -5.920 | -4.000 | -3.000 | -2.000 |
| Capex 1 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 7/20/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
15.68
USD
Average target price
58.33
USD
Spread / Average Target
+272.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.11% | 402M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- TRML Stock
- Financials Tourmaline Bio, Inc.
